Microvesicles are shed constitutively, or upon activation, from both normal and malignant cells. The process is dependent on an increase in cytosolic Ca2+, which activates different enzymes, resulting in depolymerization of the actin cytoskeleton and release of the vesicles. Drug resistance can be defined as the ability of cancer cells to survive exposure to a wide range of anti-cancer drugs, and anti-tumour chemotherapeutic treatments are often impaired by innate or acquired MDR (multidrug resistance). Microvesicles released upon chemotherapeutic agents prevent the drugs from reaching their targets and also mediate intercellular transport of MDR proteins.
Skip Nav Destination
Conference Article| January 29 2013
The role of microvesicles in cancer progression and drug resistance
Samireh Jorfi ;
Jameel M. Inal
Jameel M. Inal 1
1Cellular and Molecular Immunology Research Centre, School of Human Sciences, London Metropolitan University, 166–220 Holloway Road, London N7 8DB, U.K.
1To whom correspondence should be addressed (emailj.Inal@londonmet.ac.uk).
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
Samireh Jorfi, Jameel M. Inal; The role of microvesicles in cancer progression and drug resistance. Biochem Soc Trans 1 February 2013; 41 (1): 293–298. doi: https://doi.org/10.1042/BST20120273
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article